BiotechTubeBiotechTube
Home/Pipeline/Alpha-beta T-cell medicines

Alpha-beta T-cell medicines

Oncology

UndisclosedPartnership with Bristol-Myers Squibb

Key Facts

Indication
Oncology
Phase
Undisclosed
Status
Partnership with Bristol-Myers Squibb
Company
Editas Medicine

About Editas Medicine

Editas Medicine is a leader in the CRISPR gene editing space, aiming to discover, develop, manufacture, and commercialize a robust pipeline of genomic medicines. The company leverages two distinct CRISPR nucleases, Cas9 and Cas12a, to access a broad range of genetic mutations and develop targeted in vivo therapies. Its strategic focus includes hemoglobinopathies, in vivo editing of hematopoietic stem cells and liver, and advancing cellular therapy assets through key partnerships with Bristol-Myers Squibb and Immatics N.V.

View full company profile

Therapeutic Areas

CardiovascularHematologyOncology

Other Oncology Drugs

DrugCompanyPhase
Mvasi (bevacizumab biosimilar)ViatrisApproved
DRL-17822Dr. Reddy's LaboratoriesPhase 2
Biosimilar PortfolioZydus LifesciencesVarious
therascreen Solid TumorQiagenCommercial
GBR 830Glenmark PharmaceuticalsPhase 1
Bevacizumab BiosimilarGlenmark PharmaceuticalsApproved
Biosimilar (Bevacizumab)Ipca LaboratoriesDevelopment
LockBody Platform AssetsCentessa PharmaceuticalsPre-clinical
EverolimusAmneal PharmaceuticalsApproved
Lenalidomide (Revlimid generic)Amneal PharmaceuticalsApproved
Alymsys (bevacizumab-maly)Amneal PharmaceuticalsApproved
Pemrydi RTUAmneal PharmaceuticalsApproved